ImmuPharma/Orion (IPP-201101)

A 52-Week, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate the Efficacy and Safety of a 200-mcg Dose of IPP-201101 Plus Standard of Care in Patients With Systemic Lupus Erythematosus

 

DAIICHISANKYO PHARMA DEVELOPMENT (DS5565-A-E312)

 An open-label extension study of DS-5565 for 52 weeks in pain associated with Fibromyalgia.

 From widespread burning to localized stabbing, each sufferer experiences the pain associated with fibromyalgia differently. But one thing stays the same – the way that pain impacts on their day-to-day lives.

STARPHARMA (SLP7013-017)

JANSEN RESEARCH & DEVELOPMENT (CNTO136ARA3003)

ELI LILLY I4V-MC-JADY

ELI LILLY I4V-MC-JADZ

ELI LILLY I4V-MC-JADV

ELI LILLY ( H9B-MC-BCEI)

ELI LILLY H9B-MC-BCDX

ELI LILLY H9B-MC-BCDS

ELI LILLY I4V-MC-JADX

ELI LILLY I4V-MC-JADW

NOVARTIS (CAIN457F2302)

NOVARTIS (CQVA149A2340)

NOVARTIS (CACZ885M2301)

NOVARTIS (CAIN457F2206)

INVRAGEN (INV-DEN-203)

AMGEN (20100761)

MERCK

ABBOTT (M10889)

ABBOTT (M12-073)

TAKEDA

TAKEDA

J&J (DIA3006)

NOVARTIS

ABBOTT (L-CP07-167)

PFIZER (CV185056)

PFIZER (CV185057)

TAKEDA

NIH SUPPORTED RESEARCH